Trials / Completed
CompletedNCT05773053
A Study of NT 201 Doses in the Treatment of Platysma Prominence
A Prospective, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 Doses in the Treatment of Platysma Prominence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Merz Aesthetics GmbH · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of NT 201 in adults with moderate to severe platysma prominence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NT 201 | Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection. |
| DRUG | NT 201 Placebo | NT 201 Matching-placebo. |
Timeline
- Start date
- 2023-03-22
- Primary completion
- 2023-10-19
- Completion
- 2024-01-24
- First posted
- 2023-03-17
- Last updated
- 2024-10-21
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05773053. Inclusion in this directory is not an endorsement.